Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Astrocytoma 8Glioblastoma 5Neuroectodermal Tumors, Primitive 3Glioma 3Recurrence 2Oligodendroglioma 2Neurocytoma 2Lymphoma, Non-Hodgkin 2Brain Neoplasms 2Rhabdoid Tumor 1Pancreatic Neoplasms 1Neoplasms, Unknown Primary 1Multiple Myeloma 1Mesothelioma, Malignant 1Meningioma 1Melanoma 1Lung Neoplasms 1Gliosarcoma 1Ganglioglioma 1Esophageal Neoplasms 1Ependymoma 1Craniopharyngioma 1Carcinoma, Non-Small-Cell Lung 1Adrenocortical Carcinoma 1Adenocarcinoma Of Esophagus 1

Interventions

Mitotane 4Cisplatin 3pembrolizumab 2cixutumumab 2Etoposide 2Doxorubicin 2Dichlorodiphenyldichloroethane 2sodium thiosulfate 1relacorilant 1pegfilgrastim 1milademetan 1gossypol acetic acid 1cabozantinib 1avelumab 1antineoplaston AS 2-1 1antineoplaston A10 1Sunitinib 1Streptozocin 1Platinum 1Nivolumab 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Fentanyl 1Ethane 1Cytoreduction Surgical Procedures 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adrenocortical Carcinoma × antineoplaston A10 × Clear all
NCT00003453 2018-05-09

Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer

Burzynski Research Institute

Phase 2 Terminated
6 enrolled 6 charts
Endocrine

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡